Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Research Article

Frequency of Pathological Types of Hyperthyroidism in Thyroid Scan Patients

Author(s): Ali Pooria, Afsoun Pourya and Alireza Gheini*

Volume 17, Issue 5, 2021

Published on: 18 November, 2020

Page: [608 - 612] Pages: 5

DOI: 10.2174/1573405616666201118142752

Price: $65

Abstract

Background: Hyperthyroidism is a common systemic disorder where Graves’ disease is known as the leading cause of the disease. Thyroid stimulating hormone, T4 and T3 antibody assay is usually performed for the diagnosis of the pathology. However, with uncertainty in the results and in order to estimate the magnitude and the exact cause of the disease, radioactive iodine uptake (RAIU) test is recommended. The aim of this study is to evaluate underlying pathology in the patients presenting hyperthyroidism using RAIU test results.

Methods: This is a cross-sectional retrospective study conducted on the patients with hyperthyroidism referred to Shahid Madani Hospital in Khorramabad. Data regarding the biochemical analysis and RAIU test was collected from the records and a questionnaire based on demographic and clinical information was completed for each patient.

Results: Of 137 patients presenting hyperthyroidism, 62.04% presented with Graves’ disease, 24.08% with toxic multinodular goiter and 13.86% with toxic adenoma. 24-hour RAIU test showed that the percent of radioiodine uptake was most in toxic adenoma with 67.7%, Graves’ disease 53.5% and multinodular goiter 39%, respectively. From the age-based analysis, we found that Graves’ was most common in 20-30 years old individuals accounting for 34%, multinodular goiter in 50+ aged individuals with 36.3% and toxic adenoma was most prevalent in 30-40 and 50+ aged patients, with 26.3%. In our population of interest, 81.8% toxic multinodular goiter patients were females.

Conclusion: Our study presents the outcome of RAIU tests in hyperthyroidism based on the underlying pathologies. We also conclude, in light of other findings, that Graves’ disease is the most common cause of hyperthyroidism in our population.

Keywords: Hyperthyroidism, thyroid scan, graves' disease, RAIU test, pathology, toxic, multinodular.

Graphical Abstract

[1]
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet 2016; 388(10047): 906-18.
[http://dx.doi.org/10.1016/S0140-6736(16)00278-6] [PMID: 27038492]
[2]
Lin T, Katkar R, Garg M, Makdissi A. A rare case report of graves’disease with coexisting tsh producing pituitary adenoma. Endocr Pract 2018; 24: 222-3.
[3]
LiVolsi VA, Baloch ZW. The Pathology of Hyperthyroidism. Front Endocrinol (Lausanne) 2018; 9: 737.
[http://dx.doi.org/10.3389/fendo.2018.00737] [PMID: 30559722]
[4]
Wong M, Inder WJ. Alternating hyperthyroidism and hypothyroidism in Graves’ disease. Clin Case Rep 2018; 6(9): 1684-8.
[http://dx.doi.org/10.1002/ccr3.1700] [PMID: 30214742]
[5]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[6]
O’Rourke JA, Ravichandran C, Howe YJ, et al. Accuracy of self-reported history of autoimmune disease: A pilot study. PLoS One 2019; 14(5): e0216526.
[http://dx.doi.org/10.1371/journal.pone.0216526] [PMID: 31141520]
[7]
Taee N, Faraji Goodarzi M, Safdari M, Bajelan A. A 10-year prevalence of congenital hypothyroidism in Khorramabad (Urban Western Iran). Mol Genet Genomic Med 2019; 7(8): e817.
[http://dx.doi.org/10.1002/mgg3.817] [PMID: 31215165]
[8]
Ross DS, Burch HB, Cooper DS, et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26(10): 1343-421.
[http://dx.doi.org/10.1089/thy.2016.0229] [PMID: 27521067]
[9]
Kravets I. Hyperthyroidism: diagnosis and treatment. Am Fam Physician 2016; 93(5): 363-70.
[PMID: 26926973]
[10]
Labadzhyan A, Brent GA, Hershman JM, Leung AM. Thyrotoxicosis of pregnancy. J Clin Transl Endocrinol 2014; 1(4): 140-4.
[http://dx.doi.org/10.1016/j.jcte.2014.07.008] [PMID: 25243108]
[11]
Lipman GS, Gaudio FG, Eifling KP, Ellis MA, Otten EM, Grissom CK. Wilderness medical society clinical practice guidelines for the prevention and treatment of heat illness: 2019 update. Wilderness Environ Med 2019; 30(4S): S33-46.
[http://dx.doi.org/10.1016/j.wem.2018.10.004] [PMID: 31221601]
[12]
Sajjadi-Jazi SM, Sharifi F, Varmaghani M, Meybodi HA, Farzadfar F, Larijani B. Epidemiology of hyperthyroidism in Iran: a systematic review and meta-analysis. J Diabetes Metab Disord 2018; 17(2): 345-55.
[http://dx.doi.org/10.1007/s40200-018-0367-1] [PMID: 30918870]
[13]
Al-Muqbel KM, Tashtoush RM. Patterns of thyroid radioiodine uptake: Jordanian experience. J Nucl Med Technol 2010; 38(1): 32-6.
[http://dx.doi.org/10.2967/jnmt.109.069146] [PMID: 20159926]
[14]
Ballal S, Soundararajan R, Bal C. Re-establishment of normal radioactive iodine uptake reference range in the era of universal salt iodization in the Indian population. Indian J Med Res 2017; 145(3): 358-64.
[PMID: 28749399]
[15]
Damle N, Bal C, Kumar P, Reddy R, Virkar D. The predictive role of 24h RAIU with respect to the outcome of low fixed dose radioiodine therapy in patients with diffuse toxic goiter. Hormones (Athens) 2012; 11(4): 451-7.
[http://dx.doi.org/10.14310/horm.2002.1377] [PMID: 23422768]
[16]
Moayeri H, Haghshenas Z. Prevalence of thyrotoxicosis: clinical presentation and results of treatment in 384 patients with goiter under 18 years. Acta Med Iran 2002; 40.
[17]
Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol 2018; 14(5): 301-16.
[http://dx.doi.org/10.1038/nrendo.2018.18] [PMID: 29569622]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy